Teva Pharmaceutical Industries Limited (TEVA) Position Lowered by Pinebridge Investments L.P.

Pinebridge Investments L.P. decreased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 25.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,566 shares of the company’s stock after selling 7,796 shares during the quarter. Pinebridge Investments L.P.’s holdings in Teva Pharmaceutical Industries were worth $397,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI raised its stake in Teva Pharmaceutical Industries by 134.8% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 1,294,843 shares of the company’s stock valued at $22,789,000 after buying an additional 743,401 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Teva Pharmaceutical Industries by 72.9% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 155,965 shares of the company’s stock valued at $2,745,000 after buying an additional 65,740 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Teva Pharmaceutical Industries by 4.7% during the third quarter. Dimensional Fund Advisors LP now owns 1,035,835 shares of the company’s stock valued at $18,231,000 after buying an additional 46,229 shares in the last quarter. BB&T Securities LLC raised its stake in Teva Pharmaceutical Industries by 484.8% during the third quarter. BB&T Securities LLC now owns 112,943 shares of the company’s stock valued at $1,987,000 after buying an additional 93,630 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Teva Pharmaceutical Industries by 2.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 247,560 shares of the company’s stock valued at $4,358,000 after buying an additional 5,989 shares in the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Several analysts have issued reports on TEVA shares. TheStreet cut Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, October 26th. Finally, Credit Suisse Group lowered Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $25.00 to $13.00 in a report on Wednesday, August 23rd. Seven investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $19.18.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $0.05 during mid-day trading on Tuesday, reaching $16.39. The company had a trading volume of 17,329,042 shares, compared to its average volume of 15,790,248. Teva Pharmaceutical Industries Limited has a 1-year low of $10.85 and a 1-year high of $38.31. The company has a market cap of $16,316.96, a price-to-earnings ratio of 3.71 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is -12.10%.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Position Lowered by Pinebridge Investments L.P.” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/12/12/teva-pharmaceutical-industries-limited-teva-position-lowered-by-pinebridge-investments-l-p.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply